|Awarded On||August 20, 2014|
|Title||SHH/GLI3 Signaling Axis as a Therapeutic Target in Castration Resistant Prostate Cancer|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Thomas Boyer|
Prostate cancer is the most common malignancy and the second leading cause of cancer-associated deaths among US men. Although most prostate cancer patients initially respond to androgen deprivation therapy, they eventually progress to castration resistant prostate cancer (CRPC) characterized by androgen receptor-dependent tumor growth despite castrate levels of circulating androgens. Once patients have reached this stage, treatment options are frustratingly limited and average survival times range from 2-3 years only. Therefore, one of the overarching challenges in the field is to develop effective treatments and address mechanisms of CRPC. This innovative proposal conforms precisely to this...